MD Anderson Unveils Cancer Breakthroughs in Lung Immunotherapy and Appendix Cancer Treatment

New research from MD Anderson Cancer Center includes a global Phase 3 trial published in The Lancet Oncology, demonstrating that the novel bispecific immunotherapy ivonescimab, combined with chemotherapy, reduced cancer progression or death by 48% in patients with EGFR-mutant non-small cell lung cancer. Additionally, a study in JAMA Surgery suggests that most patients with localized appendix cancer may safely avoid chemotherapy after surgery, as it was not associated with improved survival or lower relapse risk.